Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Gonzalo de Miquel
Observed names:
G de Miquel,
G. de Miquel,
Gonzalo De Miquel
Institution:
AstraZeneca (United Kingdom)
Observed institutions:
AstraZeneca (United Kingdom),
St George's, University of London,
PHV Dialysezentrum,
Almirall (Spain),
Hochbahn (Germany),
AstraZeneca (Sweden),
AstraZeneca (Spain),
Almirall (Germany)
show all 8
OpenAlex ID:
A5014714297
Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study
2012
·
Paul W. Jones
, Dave Singh
, et al.
·
European Respiratory Journal
·
197
Characterisation and impact of reported and unreported exacerbations: results from ATTAIN
2014
·
Paul W. Jones
, Rosa Lamarca
, et al.
·
European Respiratory Journal
·
86
PDF
Lung Deposition of Aclidinium Bromide from Genuair®, a Multidose Dry Powder Inhaler
2009
·
S.P. Newman
, D.J. Sutton
, et al.
·
Respiration
·
53
Safety and Pharmacokinetics of Multiple Doses of Aclidinium Bromide, a Novel Long‐Acting Muscarinic Antagonist for the Treatment of Chronic Obstructive Pulmonary Disease, in Healthy Participants
2009
·
Josep M. Jansat
, Rosa Lamarca
, et al.
·
The Journal of Clinical Pharmacology
·
43
First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long‐acting Β2‐agonist
2014
·
Wolfgang Timmer
, Eric Massana
, et al.
·
The Journal of Clinical Pharmacology
·
21
Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD
2016
·
Jutta Beier
, Helena Pujol
, et al.
·
BMC Pulmonary Medicine
·
16
PDF
A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study
2014
·
Dave Singh
, Helena Pujol
, et al.
·
BMC Pulmonary Medicine
·
16
PDF
Abediterol (LAS100977), a novel long-acting β2-agonist: Efficacy, safety and tolerability in persistent asthma
2014
·
J. Beier
, R. Fuhr
, et al.
·
Respiratory Medicine
·
16
PDF
Efficacy, safety, and tolerability of once‐daily abediterol in patients with stable, persistent asthma: a Phase II , randomized, 7‐day, crossover study
2017
·
Jutta Beier
, Rainard Fuhr
, et al.
·
Pharmacology Research & Perspectives
·
11
PDF
Single Doses Of LAS100977, A Novel Long Acting ²2-agonist, Show High Activity And Long Duration In Healthy Subjects
2010
·
Wolfgang Timmer
, Èric Massana
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
11
Aclidinium Bromide In Patients With Chronic Obstructive Pulmonary Disease: Efficacy And Safety Results From ATTAIN
2011
·
Paul W. Jones
, A Agusti
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
9
Efficacy And Safety Of Single Inhaled Doses Of LAS100977, A Novel Long Acting ²2-agonist In Patients With Persistent Asthma
2010
·
Jutta Beier
, Rainard Fuhr
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
9
Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN
2011
·
Alvar Agusti
, Paul W. Jones
, et al.
·
European Respiratory Journal
·
7
Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study
2013
·
Jutta Beier
, Helena Pujol
, et al.
·
European Respiratory Journal
·
6
Overall and cardiovascular safety of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in patients with COPD
2015
·
Jutta Beier
, Claus Vogelmeier
, et al.
·
European Respiratory Journal
·
4
Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with moderate to severe airflow obstruction, stratified by severity
2015
·
Anthony D. D'Urzo
, Dave Singh
, et al.
·
European Respiratory Journal
·
4
Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study
2014
·
Jutta Beier
, Rainard Fuhr
, et al.
·
European Respiratory Journal
·
4
Aclidinium Bromide in Patients With Chronic Obstructive Pulmonary Disease: Improvement in Symptoms and Health Status in the ATTAIN Stud
2011
·
Paul Jones
, Alvar Agusti
, et al.
·
CHEST Journal
·
4
Aclidinium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD): Reduction in Exacerbations as Defined by Health-care Utilization and the EXACT Diary Card
2011
·
Paul Jones
, David Singh
, et al.
·
CHEST Journal
·
4
The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD)
2011
·
David Singh
, Eric D. Bateman
, et al.
·
European Respiratory Journal
·
3
Impact of the COVID-19 Pandemic on Exacerbation Rates in Patients with Asthma and/or Chronic Obstructive Pulmonary Disease in the NOVELTY Study
2022
·
H. Muellerova
, R. Hughes
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
2
P255 ATTAIN: twice-daily aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease
2011
·
D. Singh
, P. W. Jones
, et al.
·
Thorax
·
2
PDF
ATTAIN: Efficacy and Safety of Twice-Daily Aclidinium Bromide in Chronic Obstructive Pulmonary Disease (COPD)
2011
·
Paul Jones
, Eric Bateman
, et al.
·
CHEST Journal
·
2
Aclidinium bromide in patients with chronic obstructive pulmonary disease: Improvement in health status in ATTAIN
2011
·
Paul W. Jones
, Alvar Agusti
, et al.
·
European Respiratory Journal
·
2
A randomized placebo controlled trial of AZD8999 (LAS190792) a novel dual acting bronchodilator in asthmatics
2017
·
Carol Astbury
, Helena Pujol
, et al.
·
European Respiratory Journal
·
1
Show more works
View as search
Works count:
37
Citation count:
534
H-index:
10
I10-index:
10
Year
Topic
Type